Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-VLP-SUDV
- Development stage
- Preclinical
- Lead developer
- GeoVax Labs
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-VLP-SUDV is an investigational vaccine candidate developed by GeoVax Labs in collaboration with the University of Texas Medical Branch (UTMB) for the prevention of Sudan ebolavirus (SUDV) infection. The vaccine utilizes GeoVax's proprietary Modified Vaccinia Ankara (MVA) viral vector platform, which is engineered to express the SUDV glycoprotein (GP) and matrix protein (VP40) within the vaccinated individual. These proteins self-assemble into non-infectious virus-like particles (VLPs) that mimic the structure of the native virus, thereby inducing a robust and comprehensive immune response—including both neutralizing antibodies and T-cell activity—without the risk of viral replication. Preclinical studies in guinea pig lethal challenge models have demonstrated that a single dose of MVA-VLP-SUDV provides 100% protection against SUDV. The development program is supported by collaborations with the National Institute of Allergy and Infectious Diseases (NIAID) and the U.S. Army.
- Other names
- Sudan ebolavirus vaccineGeoVax Sudan ebolavirus vaccine
02
Targets
VP40 (Ebola virus matrix protein VP40)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on MVA-VLP-SUDV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-VLP-SUDV.